EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life

Anastasia Shchendrygina, Amina Rakisheva, Ilya Giverts, Yasmin Rustamova, Anzhela Soloveva

Cardiac Failure Review · 11.09.2024 · 10

DOI: 10.15420/cfr.2024.05 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiac Failure Review, online erschienen am 11.09.2024. Verfasst von Anastasia Shchendrygina und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Therapy No. 2, IM Sechenov First Moscow State Medical University Moscow, Russia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have garnered attention for their cardiovascular benefits beyond glycaemic control in patients with type 2 diabetes, exhibiting patterns previously seen in cardiovascular outcomes trials on sodium–glucose cotransporter 2 inhibitors, which now receive a high level of recommendation for the treatment of heart failure (HF). GLP-1 RAs have been increasingly investigated in HF cohorts, but mainly in small-scale studies reporting inconclusive findings regarding clinical outcomes and different safety profiles in HF patients with reduced and preserved ejection fractions. This review discusses the effects of GLP-1 RAs on surrogate HF outcomes, such as cardiac structure and function, exercise capacity and quality of life, in HF patients across the spectrum of left ventricular ejection fraction, to provide insights into the potential of these agents to be investigated in large clinical trials to evaluate clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

Glucagon-like peptide-1 receptor agonistscardiac functionexercise capacityheart failurequality of life

Autor:innen und Institutionen

  • Department of Hospital Therapy No. 2, IM Sechenov First Moscow State Medical University Moscow, Russia.
  • Department of Cardiology, City Cardiology Center Almaty, Kazakhstan.
  • Department of Internal Medicine, Maimonides Medical Center Brooklyn, NY, US.
  • The Cardiovascular Research Center, Massachusetts General Center Boston, MA, US.
  • Department of Internal Medicine, Educational-Surgery Clinic, Azerbaijan Medical University Baku, Azerbaijan.
  • Department of Cardiology, Almazov National Medical Research Centre St Petersburg, Russia.

Zitieren

APA

Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. (2024). Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life. Cardiac Failure Review, 10. https://doi.org/10.15420/cfr.2024.05

Vancouver

Shchendrygina A, Rakisheva A, Giverts I, Rustamova Y, Soloveva A. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life. Cardiac Failure Review. 2024;10. doi:10.15420/cfr.2024.05

BibTeX
@article{Shchendrygina2024,
  author = {Shchendrygina, Anastasia and Rakisheva, Amina and Giverts, Ilya and Rustamova, Yasmin and Soloveva, Anzhela},
  title = {Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life},
  journal = {Cardiac Failure Review},
  year = {2024},
  volume = {10},
  doi = {10.15420/cfr.2024.05}
}
Kostenlos starten →